AQR reports 3.16M Haemonetics (HAE) shares in passive 13G filing
Rhea-AI Filing Summary
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report a passive ownership stake in Haemonetics Corp3,163,104 shares of Haemonetics common stock, representing 6.76% of the class as of 12/31/2025.
The firms report no sole voting or dispositive power over the shares, but shared voting and shared dispositive power over all 3,163,104 shares. They certify the position was acquired and is held in the ordinary course of business, not to change or influence control of Haemonetics.
Positive
- None.
Negative
- None.
Insights
AQR discloses a passive 6.76% stake in Haemonetics.
AQR Capital Management, LLC and its parent report beneficial ownership of 3,163,104 Haemonetics shares, equal to 6.76% of the common stock as of 12/31/2025. All voting and dispositive authority is reported as shared, with no sole control over the position.
The certification states the stake is held in the ordinary course of business and not for the purpose of changing or influencing control. This aligns with a Schedule 13G passive investment. Any future impact depends on changes in ownership level or filing status disclosed in subsequent reports.
FAQ
Is AQR’s ownership in Haemonetics (HAE) considered passive or for control purposes?
Who are the reporting persons in the Haemonetics (HAE) Schedule 13G filing?
What key date is associated with AQR’s Haemonetics (HAE) ownership in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.